OncoMatch/Clinical Trials/NCT06647901

Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study

Is NCT06647901 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies ICG (Indocyanine Green) for giant cell tumor of bone.

Phase 1/2RecruitingTang XiaodongNCT06647901Data as of Jun 2026Location: China

Treatment: ICG (Indocyanine Green) — ICG fluorescence imaging will be applied during the intralesional curettage of giant cell tumor of bone in the limbs. This study aims to preliminarily explore whether ICG fluorescent-guided curettage could find small residual tumors and reduce the recurrence rate of tumor.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

ICG (Indocyanine Green)

Demographics

Ages ≤ 65

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: RANKL inhibitor (denosumab)

Denosumab ... not used before surgery.

Cannot have received: diphosphonate (diphosphonates)

diphosphonates are not used before surgery.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06647901 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Is there an age limit?

Yes. Patients must be 65 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify